Teladoc Health, Inc. (TDOC)
NYSE: TDOC · IEX Real-Time Price · USD
13.14
+0.01 (0.08%)
Apr 17, 2024, 4:00 PM EDT - Market closed
Teladoc Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Teladoc Health stock have an average target of 23.21, with a low estimate of 17 and a high estimate of 29. The average target predicts an increase of 76.64% from the current stock price of 13.14.
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2024.
Analyst Ratings
The average analyst rating for Teladoc Health stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 9 | 9 | 9 | 9 | 8 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 5, 2024 |
| Truist Securities | Truist Securities | Hold Maintains $23 → $17 | Hold | Maintains | $23 → $17 | +29.38% | Mar 6, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $22 | Buy | Initiates | $22 | +67.43% | Feb 29, 2024 |
| Leerink Partners | Leerink Partners | Hold Initiates $17 | Hold | Initiates | $17 | +29.38% | Feb 26, 2024 |
| DA Davidson | DA Davidson | Hold Maintains $22 → $18 | Hold | Maintains | $22 → $18 | +36.99% | Feb 21, 2024 |
Financial Forecast
Revenue This Year
2.72B
from 2.60B
Increased by 4.52%
Revenue Next Year
2.82B
from 2.72B
Increased by 3.64%
EPS This Year
-1.05
from -1.34
EPS Next Year
-0.72
from -1.05
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.8B | 3.0B | 3.1B | 3.6B | 3.8B |
| Avg | 2.7B | 2.8B | 2.9B | 3.3B | 3.7B |
| Low | 2.6B | 2.7B | 2.7B | 3.1B | 3.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.3% | 9.3% | 9.0% | 22.4% | 13.1% |
| Avg | 4.5% | 3.6% | 3.5% | 14.7% | 9.9% |
| Low | -0.7% | -1.9% | -2.9% | 6.3% | 5.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.77 | -0.17 | 0.66 | 0.12 |
| Avg | -1.05 | -0.72 | -0.38 | 0.11 |
| Low | -1.35 | -1.15 | -0.90 | 0.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.